What Is Stem Cell Therapy Used For? The 2026 Evidence Ladder

Introduction: Why “What Is Stem Cell Therapy Used For?” Doesn’t Have a Simple Answer

Stem cell therapy holds an unusual place in modern medicine. It is one of the field’s most proven tools: bone marrow transplants have saved lives for decades. It is also one of the most hyped and misunderstood, attached to everything from joint injections to promised “cures” for neurological disease.

People who search for this topic usually find two kinds of results. Some are dense medical journal articles written for specialists. Others are short listicles that place approved treatments next to speculative ones with no distinction. Neither helps a reader figure out where their own condition falls.

This article uses a different approach: a three-rung Evidence Ladder that sorts major use cases by scientific and regulatory maturity rather than by marketing appeal:

• Established: FDA-approved, standard-of-care uses
• Emerging: uses supported by randomized trials but still investigational
• Experimental: early-phase research with promise but no validation yet

Within a few minutes, readers should be able to place their situation on the ladder and see what level of evidence supports it. The 2026 regulatory picture, including FDA approvals and the 361 HCT/P framework, is explained openly throughout.

What Stem Cell Therapy Actually Is (A 60-Second Primer)

Stem cells are undifferentiated cells. They can develop into specialized cell types, release signals that support tissue repair, or both. Patients usually encounter three broad categories:

• Hematopoietic stem cells (HSCs): Blood-forming cells, the basis of bone marrow and peripheral blood stem cell transplants.
• Mesenchymal stem/stromal cells (MSCs): Cells studied mainly for their signaling and anti-inflammatory effects. They are central to orthopedic applications and many other areas of research.
• Donor-derived and reprogrammed cells: Cells that are engineered or coaxed in the laboratory into specific types, such as dopamine-producing neurons. These drive much of the newest neurological research.

“Stem cell therapy” is an umbrella term. A bone marrow transplant for leukemia and an ultrasound-guided knee injection share the label, but they differ greatly in procedure, risk, and regulatory status. That is why a tiered framework is needed.

The source of the cells also matters. Bone marrow, umbilical cord blood, adipose (fat) tissue, and peripheral blood each come with different considerations, and they come up repeatedly on the ladder below.

The 2026 Evidence Ladder: A Framework for Making Sense of the Claims

Stem cell claims do not all deserve the same level of trust. Grouping them together is a major reason patients end up confused or misled. The ladder separates them into three rungs.

Rung 1: Established. These therapies are FDA-approved, considered standard of care, and backed by decades of outcomes data in many cases.

Rung 2: Emerging. These uses have support from randomized controlled trials (RCTs) and meta-analyses and are offered in clinical practice. They are still technically investigational for their specific indications, or they operate under a different regulatory pathway than full drug approval.

Rung 3: Experimental. These are early-phase studies, often with small cohorts and short follow-up. The promise is real but not yet validated. Most of the high-profile neurological, renal, and sensory applications sit here.

The ladder is not meant to steer anyone away from legitimate options. Its purpose is to help readers set realistic expectations and ask any provider better questions.

Rung 1: Established Uses (FDA-Approved, Standard of Care)

The main established use is hematopoietic stem cell transplantation (HSCT). According to the Harvard Stem Cell Institute and other major academic sources, HSCT has long been the only broadly FDA-approved stem-cell-based therapy. It typically takes the form of a bone marrow or peripheral blood stem cell transplant, and the cells can also come from umbilical cord blood.

The scale is substantial. More than 25,000 HSCTs are performed in the U.S. each year for:

• Lymphoma and leukemia
• Immune-deficiency illnesses
• Congenital metabolic defects
• Hemoglobinopathies (such as sickle cell disease and thalassemia)
• Myelodysplastic and myeloproliferative syndromes

The list of diseases treated with HSCT now exceeds 70. More than half of autologous transplants (which use the patient’s own cells) are performed for multiple myeloma and non-Hodgkin lymphoma.

A small group of narrowly approved cell therapies completes this tier:

• Ryoncil (remestemcel-L): The first FDA-approved mesenchymal stromal cell therapy and the first off-the-shelf allogeneic cell therapy. It was approved in December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients two months and older.
• Omisirge: A processed cord blood product approved for certain blood cancer patients scheduled to undergo cord blood transplantation.
• MACI: The patient’s own cartilage cells, cultured and implanted to repair specific knee cartilage defects. This is a useful point of reference for orthopedic readers, because it shows that a cell-based knee therapy can reach full approval for a narrow, well-defined indication.
• Lantidra: Donor pancreatic islet cells for certain adults with type 1 diabetes who have recurring severe low blood sugar.

Takeaway: A condition on this list is treated with standard, protocol-driven, insurance-recognized medicine. It is not an investigational choice. These treatments are managed by specialists such as hematologists and oncologists through conventional medical channels.

Rung 2: Emerging Uses (Strong Evidence, Still Investigational)

For most readers, this tier matters most in practical terms. These treatments have real RCT and meta-analysis data behind them and are available in clinics today. They are not FDA-approved for the specific indication.

Knee osteoarthritis is the leading example and the most-studied emerging application.

The evidence points in a generally positive direction but warrants caution:

• Positive results: A dose-focused meta-analysis of 300 patients found a pooled standardized mean difference in WOMAC score of –1.35 at 12 months. That indicates a moderate-to-large treatment effect, with intra-articular MSC therapy significantly improving clinical outcomes at one year.
• Cautious results: A broader 2025 meta-analysis of 28 RCTs concluded that stem cell therapies appear to be primarily symptom-modifying rather than structure-modifying. In other words, they may ease pain and improve function without clearly rebuilding cartilage. The authors called for larger, standardized trials to identify the best preparations and the patients most likely to benefit.
• Certainty of the evidence: Broader systematic reviews generally rate the certainty of this evidence as low. Modest improvement in pain and function is plausible, but the therapy is not yet a proven standard of care.

Research activity is growing quickly. 224 clinical trials worldwide are currently studying stem cell therapies for osteoarthritis alone, and a major, well-funded Phase III trial was announced in January 2026. Knee osteoarthritis may move up the ladder in the coming years.

Some tendon and ligament applications also belong in this tier. They have encouraging but less mature data, and claims about them should be held to the same standard.

Most of these treatments are not “FDA-approved drugs.” They usually operate under a specific regulatory pathway called the 361 HCT/P framework, which is explained in its own section below.

Rung 3: Experimental Uses (Early-Phase, High-Hype, Not Yet Validated)

This tier includes some of the most exciting science in medicine. “Early-phase,” however, means small trials, short follow-up periods, and results that have not been replicated at scale.

Parkinson’s Disease

Parkinson’s has produced the most newsworthy developments of 2025 and 2026:

• A donor-derived, stem-cell-reprogrammed dopamine-neuron therapy became the first therapy of its kind approved for Parkinson’s anywhere. Two caveats are important: the approval came from a regulator outside the U.S., not the FDA, and it was based on a trial of just seven patients followed for two years.
• Three landmark 2025 trials in Japan, the USA, and South Korea, each using different stem cell sources, showed dose-dependent motor improvements on MDS-UPDRS Part III scores. Together they demonstrated safety, feasibility, and early signs of efficacy.
• The STEM-PD Phase I/II trial shows what research at this stage looks like. It enrolled people with moderately advanced Parkinson’s who still had significant symptoms despite optimized medication, and transplanted stem cell-derived dopaminergic progenitor cells designed to replace lost dopamine-producing neurons.

These results are promising, but they remain at the feasibility and safety stage.

Spinal Cord Injury

A meta-analysis of 62 studies involving 2,439 patients concluded that current evidence is not strong enough to support clinical translation of stem cell therapy for spinal cord injury, and that several problems remain unresolved.

Heart Failure and Myocardial Infarction

The effects of stem cell therapy in heart failure remain controversial. The safety and effectiveness of umbilical-cord-derived MSC therapy for cardiac use have not been proven.

Autoimmune Disease

HSCT is being studied for severe autoimmune disorders, including scleroderma, multiple sclerosis, ulcerative colitis, and Crohn’s disease. Results in multiple sclerosis have been encouraging, but the FDA has not approved stem cell transplantation as an MS treatment. The agency explicitly warns patients against unapproved procedures because of safety concerns.

Other Frequently Promoted Categories

Kidney (renal) and hearing applications also attract a great deal of marketing. They have preliminary research only, with no approved or standardized protocols.

The common thread: Experimental does not mean fraudulent. It means patients should ask for trial data, not testimonials, before considering any option in this tier.

The Regulatory Reality Check: Understanding the 361 HCT/P Framework

Most patient confusion, and most bad-actor clinics, exist in the gap between “FDA-approved” and “FDA-regulated.”

FDA-approved stem cell therapies are limited mainly to blood cancers, hematologic conditions, and the short list of products described in Rung 1.

361 HCT/P products are minimally manipulated human cells and tissues, such as a patient’s own bone marrow or adipose-derived cells. They can be offered legally under a separate regulatory framework without full FDA drug approval if they meet specific criteria:

• Minimal manipulation: The cells are not significantly altered from their original state.
• Homologous use: The cells perform the same basic function in the recipient as they did in the donor tissue.
• No combination with other articles: With limited exceptions, the cells are not combined with drugs or devices.

Most outpatient orthopedic stem cell and PRP procedures, including those in the Emerging tier, operate under this 361 framework. They are not FDA-“approved” drugs. This is not a red flag in itself, but patients deserve to understand the distinction before they consent to treatment.

The contrast with illegitimate practice is clear. The FDA has issued warning letters to clinics whose cellular products do not meet good manufacturing practice requirements and are illegally marketed for conditions where they have not been shown to be safe or effective.

The consequences of unproven treatment can be severe. The International Society for Stem Cell Research has noted that a number of Americans have been blinded or paralyzed by unproven stem cell treatments. In one documented case, three patients who received an unregulated autologous stem cell procedure for macular degeneration developed epiretinal membranes and delayed, severe retinal detachments. At one year, their vision ranged from 20/200 to no light perception.

As of 2026, an estimated several thousand U.S. clinics have offered unapproved stem cell injections for conditions ranging from joint pain to neurological disease, and federal regulators have steadily increased enforcement.

How to Use the Evidence Ladder for Your Own Situation

The self-check takes three steps: identify the condition, find its rung using the sections above, and set expectations to match.

• If Established: Expect the treatment to be discussed as standard care, typically by a hematologist or oncologist, and handled through conventional medical channels.
• If Emerging: Expect the provider to be open about 361 HCT/P status, to describe realistic outcomes (symptom relief rather than guaranteed structural repair), and to point to RCT or meta-analysis data, not just testimonials.
• If Experimental: Expect enrollment in a registered clinical trial, searchable on ClinicalTrials.gov, to be the appropriate route. A paid outpatient procedure at a general wellness clinic is not.

Questions every patient should ask any provider:

1. Is this treatment FDA-approved, or does it operate under the 361 HCT/P framework?
2. What published RCT or meta-analysis data supports this specific use?
3. What are the realistic, evidence-based outcomes I can expect, as opposed to anecdotal ones?
4. How will the injection be delivered and guided?
5. What makes me a suitable candidate, or not a suitable one?

Where This Leaves Orthopedic and Joint-Pain Patients

Most real-world demand and investment in stem cell therapy is focused on musculoskeletal conditions. Industry analysts project that the musculoskeletal disorders segment will hold the largest share (40.7%) of stem cell therapy applications in 2026. Mesenchymal stem cells are estimated to account for roughly 45% of the broader stem cell therapy market this year. Orthopedic MSC use has become central to the field even though it remains on the Emerging rung.

The main caveat still applies: current evidence suggests the benefits are primarily symptom-modifying, not structurally regenerative. For carefully selected patients, though, symptom relief can be clinically meaningful. This is especially true for people weighing a regenerative option against major surgery such as total knee replacement.

More than 600,000 knee replacements are performed in the U.S. each year, and studies suggest up to 80% of patients told they need total knee replacement may not actually require surgery. For that reason, evidence-aligned regenerative options deserve an open conversation with a qualified provider.

Patients whose conditions fall on the Emerging rung, such as knee osteoarthritis, tendon and ligament injuries, and joint degeneration, are the group for whom a provider’s regulatory transparency and clinical rigor matter most.

Unicorn Bioscience illustrates what evidence-aligned Emerging-tier care looks like in practice. The U.S.-based provider operates within the 361 HCT/P framework and says so publicly: its materials note that as of 2026, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions. All of its injections are delivered with precision imaging guidance (ultrasound or X-ray). Treatment protocols are personalized according to inflammation levels, age, injury type and location, current medications, and individual health goals. This kind of disclosure and individualized planning is what patients on the Emerging rung should expect from any provider.

Conclusion: Climbing the Ladder With Clear Eyes

“Stem cell therapy” is not one treatment with one answer. It covers a wide range:

• Proven for decades: HSCT for blood cancers and immune disorders
• Clinically useful but investigational: orthopedic MSC therapy for conditions such as knee osteoarthritis
• Promising but unproven: Parkinson’s disease, spinal cord injury, cardiac, and autoimmune applications

The honest answer to “what is stem cell therapy used for?” depends on which rung a given condition occupies. Transparency about regulatory status (FDA-approved, 361 HCT/P, or clinical-trial-only) is the most reliable way to separate credible care from risky hype.

A patient who understands the ladder is much better prepared for a productive, safe conversation with any provider, whether traditional or regenerative.

Next Step: Find Out If Your Condition Fits the Emerging, Evidence-Supported Tier

Readers whose situation falls in the orthopedic or musculoskeletal Emerging tier, such as knee osteoarthritis, rotator cuff or meniscus injuries, tendon and ligament damage, or chronic joint pain, can take the next step with a personalized consultation.

Unicorn Bioscience offers virtual and in-person consultations at eight locations across Texas (Austin, Dallas, El Paso, Fort Worth, Houston, and San Antonio), Florida (Boca Raton), and New York (Manhattan). Patients can expect:

• Precision-guided injections using ultrasound and X-ray imaging
• Multiple treatment options, including stem cell therapy, PRP, BMAC, exosome therapy, hyaluronic acid injections, and peptide therapy
• Personalized protocols based on individual patient factors rather than a one-size-fits-all approach
• Same-day treatment availability for qualified candidates

To discuss where a specific condition falls on the evidence ladder and which options are realistic, call (737) 347-0446 to schedule a consultation.

A provider who discusses regulatory status openly, explaining what is approved, what is investigational, and what the evidence actually shows, is demonstrating the kind of trustworthy, evidence-aligned care every patient should expect.